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Abstract
Objectives To investigate whether changes to the apparent
diffusion coefficient (ADC) of primary tumour in the early
period after starting chemotherapy can predict progression-
free survival (PFS) or overall survival (OS) in patients with
unresectable pancreatic adenocarcinoma.
Methods Subjects comprised 43 patients with histologically
confirmed unresectable pancreatic cancer treated with first-
line chemotherapy. Minimum ADC values in primary tumour
were measured using the selected area ADC (sADC), which
excluded cystic and necrotic areas and vessels, and the whole
tumour ADC (wADC), which included whole tumour com-
ponents. Relative changes in ADC were calculated from base-
line to 4 weeks after initiation of chemotherapy. Relationships
between ADC and both PFS and OS were modelled by Cox
proportional hazards regression.
Results Median PFS and OS were 6.1 and 11.0 months, re-
spectively. In multivariate analysis, sADC change was the
strongest predictor of PFS (hazard ratio (HR), 4.5; 95 % con-
fidence interval (CI), 1.7–11.9; p=0.002). Multivariate Cox
regression analysis for OS revealed sADC change and CRP
as independent predictive markers, with sADC change as the
strongest predictive biomarker (HR, 6.7; 95 % CI, 2.7–16.6;
p=0.001).
Conclusion Relative changes in sADC could provide a useful
imaging biomarker to predict PFS and OS with chemotherapy
for unresectable pancreatic adenocarcinoma.
Key Points
• Relative change in ADC value can predict survival in
unresectable pancreatic cancer.
• ADC change could determine a chemosensitivity of pancre-
atic cancer.
• ADC values should be measured by excluding cystic, necrot-
ic areas and vessels.
Keywords Pancreatic cancer . Apparent diffusion
coefficient . Biomarker . Prognostic factor . MRI
Introduction
Patients with unresectable pancreatic cancer show a poor
prognosis, with overall survival of 5.6–10.1 months.
Currently, gemcitabine or oral fluoropyrimidines, including
capecitabine and S-1, are recommended as first-line chemo-
therapies [1–4]. The choice of first-line chemotherapy is thus
currently determined by the individual physician. Pancreatic
cancer is an aggressive disease and patient condition often
deteriorates rapidly after the failure of first-line chemotherapy.
Median survival with second-line chemotherapies is only 3–
5 months [5, 6]. Choice of an effective first-line chemotherapy
is thus vital to improve the patient’s prognosis.
Determining the chemosensitivity of an unresectable pan-
creatic cancer represents a major challenge. If the therapeutic
effect can be predicted in the early period after starting che-
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The apparent diffusion coefficient (ADC) calculated
from diffusion-weighted imaging (DWI) has been pro-
posed as a non-invasive imaging biomarker [7–11].
DWI is sensitive to structural properties at the cellular
level, and thus has the potential to detect and quantify
cellular changes in the tumour microenvironment arising
after the initiation of cancer therapy [12]. Several au-
thors have reported promising results demonstrating that
changes in ADC from baseline could provide early pre-
diction of therapeutic effects with treatments such as
chemoradiotherapy for head and neck cancer and che-
motherapy for liver metastases [13–16]. Two investiga-
tors reported the usefulness of pretreatment ADC values
for prediction of response to chemotherapy or chemora-
diotherapy in pancreatic cancer [17, 18]. However, to
date, the usefulness of a relative change in ADC during
treatment of pancreatic cancer has not yet been evaluat-
ed. This study was therefore conducted to investigate
whether changes in ADC on DWI could provide a sen-
sitive biomarker to predict progression-free survival
(PFS) and overall survival (OS) in the early chemother-




All study protocols for this single-centre prospective trial were
approved by the institutional review board of our hospital.
Patients who had been diagnosed with unresectable pancreatic
adenocarcinoma underwent DWI before and 4 weeks after
initiation of chemotherapy and ADC values of the primary
pancreatic tumour were determined. Chemotherapy continued
until tumour progression based on a clinical practice protocol.
The goal of this study was to assess the correlations between
relative changes in ADC and PFS or OS using uni- and mul-
tivariate Cox regression analyses.
Study subjects
Written informed consent was obtained from all patients. All
tumours were histologically confirmed as adenocarcinoma by
fine-needle biopsy before treatment. The eligibility criteria
were as follows: (i) no prior treatment; (ii) maximum diameter
of pancreas tumour >1 cm; (iii) Eastern Cooperative
Oncology Group performance status (ECOG PS) of 0–2;
and (iv) adequate bone marrow, kidney and liver function.
The exclusion criterion was the presence of a contraindication
for magnetic resonance imaging (MRI).
Treatment regimens
The following three chemotherapy regimens were used [1, 4,
19, 20]: gemcitabine alone (at a dose of 1,000 mg/m2 once
weekly for 3 weeks, followed by 1 week of rest); S-1 alone (at
a dose of 80 mg/m2 in divided doses twice daily for 28 days,
followed by 14 days of rest); or gemcitabine plus S-1
(gemcitabine at a dose of 1,000 mg/m2 once weekly for
2 weeks followed by 1 week of rest; S-1 at a dose of 60 mg/
m2 in divided doses twice daily during 14 days followed by
7 days of rest). The chemotherapy regimen was decided by
physicians’ preferences, i.e. surgeons or medical oncologists.
All treatments were continued until disease progression as
judged by Response Evaluation Criteria in Solid Tumour
(RECIST) criteria [21] or the appearance of severe toxicity.
Magnetic resonance imaging (MRI) technique
MRI was performed using a 1.5-T system (Magnetom
Symphony Sonata; Siemens Medical Systems, Erlangen,
Germany) with a four-channel phased array coil before and
4 weeks after the start of chemotherapy. Conventional imag-
ing of the upper abdomen was acquired for all patients using
the following sequences: T1-weighted breath-hold gradient-
echo (repetition time (TR), 153 ms; echo time (TE), 2.44 ms;
flip angle, 90°; field of view (FOV), 350 mm; matrix, 256×
256; number of slices, 19; thickness, 8 mm; acquisition time,
20 s) and T2-weighted breath-hold turbo spin-echo (TR, 4,
400 ms; TE, 95 ms; echo train length, 33; FOV, 350 mm;
matrix, 256×256; number of slices, 19; thickness, 8 mm; ac-
quisition time, 24 s). DWI was obtained using a free-
breathing single-shot echo-planar sequence (TR, 1,
400 ms; TE, 67 ms; EPI factor, 128; FOV, 350 mm;
matrix, 128×128; PAT factor, 2; PAT mode, parallel
imaging with GRAPPA; number of slices, 26; thickness,
7 mm; number of excitations, 2; fat saturation, CHESS
method; acquisition time, 2 min 41 s). DWI was obtain-
ed under free breathing with virtual respiratory monitor-
ing using navigator echoes (prospective acquisition cor-
rection technique). Diffusion gradients were applied
with three b-values (b=0, 500 and 1,000 s/mm2) in
three directions and combined to produce a trace dataset
to minimize the effect of diffusion anisotropy, which
was the same technique as that used in a previous study
[22]. ADC maps were calculated automatically by the
MRI system. ADC was calculated using the following
formula:
ADC ¼ ln SI1=SI2ð Þ= b2 − b1ð Þ
where b1 and b2 are the motion-probing gradient factors
(diffusion factors) of sequences S1 and S2, and SI1 and
SI2 are the signal intensities in these sequences.
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Analysis of apparent diffusion coefficient (ADC) data
ADC values were measured using the following two tech-
niques; (1) the selected area ADC (sADC): five regions of
interest (ROIs) with a mean size of 1.55 cm2 (range; 1.14–
2.76) were manually placed on the same slice of the largest
tumour diameter, excluding cystic and necrotic areas and ves-
sels, which were detected by contrast enhanced CT and MRI
obtained before treatment. Their minimum value was defined
as a sADC value. (2) the whole tumour ADC (wADC): ROIs
were manually measured by encompassing the whole tumour
including cystic and necrotic areas and vessels on the largest
tumour diameter. The minimum ADC value inside of the
ROIs was defined as a wADC value. These measurements
were determined by agreement of experienced diagnostic ra-
diologists (H.N. and N.M.). The relative change in ADC was
determined using the following formula: the change in
ADC=(ADC at 4 weeks – ADC pre)/(ADC pre×100 %).
An increase in ADC value was defined as a positive ADC
change and the same or a decrease in ADC value was defined
as a negative ADC change.
Assessment of therapeutic effect and evaluation
The CT protocol included a non-enhanced scan followed by
arterial and delayed-phase acquisitions after intravenous injec-
tion of iodized contrast medium (100–150mL; range of iodine
concentration, 300–370 mgI/mL) at a flow rate of 3–4 mL/s.
Tumour response was evaluated according to RECIST criteria
using CT performed every 2 months. PFS was calculated as
the time interval from the initiation of treatment to the date of
disease progression. If no disease progression was observed,
PFS was calculated from the initiation of treatment to the last
day of follow-up or the date of death. OSwas calculated as the
time interval from the initiation of treatment to the date of
death or to the last day of the follow-up period.
Selection of other predictive biomarkers
Based on previous reports [21–23], the following additional
biochemical markers were evaluated: serum carbohydrate an-
tigen (CA) 19-9 (CA19-9), carcinoembryonic antigen (CEA),
lactate dehydrogenase (LDH) and C-reactive protein (CRP).
Relative changes in these biochemical markers at 4 weeks
after initiation of treatment compared to baseline were calcu-
lated. In addition, changes in the longest diameter of pancre-
atic tumour between baseline and 4 weeks after initiation of
chemotherapy were evaluated using contrast-enhanced CT.
Statistical analysis
All statistical analyses were conducted using SPSS version
17.0 statistical software (SPSS; Chicago, IL, USA). PFS and
OS were estimated using the Kaplan-Meier method, and 95 %
Fig. 1 Overall survival (OS) and progression-free survival (PFS) curves.
Median overall PFS and OS were 6.1 months (95 % CI, 4.5–7.7) and
11.0 months (95 % CI, 7.9–14.1), respectively
Table 1 Patient characteristics (N=43)
Characteristics Patients (%)
Age (years)

















Gemcitabine plus TS-1 12 (28.0)
Previous CA19-9 (U/mL)
Median (range) 761 (1–28,487)
Previous CEA (ng/ml)
Median (range) 7.8 (1.6–311)
ECOGPS = Eastern Cooperative Oncology Group performance status,
CA19-9 = carbohydrate antigen 19-9, CEA = carcinoembryonic antigen
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confidence intervals (CIs) were provided for proportions. Uni-
and multivariate Cox regression analyses were performed to
assess predictive markers for PFS and OS, including relative
changes to ADC, CA19-9, CEA, LDH, CRP and tumour size.
Cut-off values for these biomarkers were defined as 0 % in
ADCs and tumour size, and 20 % in CA19-9, CEA, LDH and
CRP based on previous reports [23–25]. Survival curves for
PFS and OS were compared between groups using the log-
rank test. Multivariate analysis was undertaken for variables
demonstrating values of P<0.10 after univariate analysis, and
P<0.05 was considered statistically significant.
Results
Patient and tumour characteristics
Patient and tumour characteristics are summarized in Table 1.
A total of 45 patients were initially enrolled, but two patients
dropped out because they could not undergo follow-up DWI.
The remaining 43 patients (19 women, 24 men; median
age, 67 years; range, 40–82 years) were analysed.
Tumour stage according to the TNM classification system
published by the International Union Against Cancer, 6th
edition was stage III disease in ten patients (23.3 %) and
stage IV disease in 33 patients (76.7 %). Liver metastases
were observed in 22 patients (51.2 %), lymph node metas-
tases in nine patients (20.9 %), lung metastases in seven
patients (16.3 %) and peritoneal dissemination in six pa-
tients (14 %) at the time of primary diagnosis before initi-
ation of therapy. Median pretreatment pancreatic tumour
size was 4.0 cm in diameter (range, 2.1–7.3 cm). Median
baseline levels of CA19-9 and CEA were 761 U/mL
(range, 1–28,487 U/mL) and 7.8 ng/mL (range, 1.6–
311 ng/mL), respectively.
Therapeutic effect and survival
Median duration of follow-up was 11.0 months (range, 2.6–
42.1 months). Five patients (11.6 %) achieved partial re-
sponse, whereas the remaining 38 patients were judged as
showing stable disease or progressive disease. Median PFS
was 6.1 months (95 % CI, 4.5–7.7 months) and median OS
was 11.0 months (95 % CI, 7.9–14.1 months) (Fig. 1). After
failure of first-line chemotherapy, 28 patients (65.1 %) re-
ceived second-line therapy, as follows: gemcitabine plus S-1
in ten patients (35.7 %); S-1 in 11 patients (39.3 %); S-1 plus
oxaliplatin in three patients (10.7%), gemcitabine plus hepatic
arterial chemoinfusion in two patients (7.1 %), and
gemcitabine plus radiotherapy in two patients (7.1 %). Mean
duration of treatment with second-line chemotherapy was
2.8 months. Two patients (4.7 %) who had obtained marked
tumour shrinkage with first-line chemotherapy underwent cu-
rative surgical resection. The remaining 13 patients (30.2 %)
received best supportive care.
Predictive biomarkers
The sADC values before treatment and at 4 weeks after initi-
ation of chemotherapy were 1.10±0.14 mm2/sec and 1.15±
0.20×10-3 mm2/sec, respectively. The wADC values before
and 4 weeks after treatment were 1.03±0.14 mm2/sec and
1.09±0.19×10-3 mm2/sec, respectively. In sADC, 28 positive
ADC changes and 15 negative ADC changes were seen, while
in wADC, 27 positive ADC changes and 16 negative ADC
changes were seen.
Uni- and multivariate analyses of early predictive markers
for PFS are shown in Table 2. Multivariate analysis revealed
sADC change, CRP and tumour size as independent predic-
tive markers for PFS, and sADC change was the strongest of
these (HR, 4.5; 95%CI, 1.7–11.9; p=0.002). Figure 2a shows
Kaplan-Meier curves for PFS in the positive sADC change
Table 2 Uni- and multivariate analyses of predictive markers for progression-free survival
Factors Pts Univariate Multivariate
P HR 95%CI P HR 95%CI
sADC (0% =>) 15 0.001 5.3 2.3- 11.9 0.002 4.5 1.7- 11.9
wtADC (0%=>) 16 0.525 1.3 0.6- 2.6
CA 19–9 (20%<) 10 0.097 1.9 0.9- 4.3 0.345 1.6 0.6- 3.9
CEA (20%<) 10 0.216 1.7 0.7- 3.8
CRP (20%<) 12 0.001 3.7 1.7- 7.9 0.011 2.9 1.3- 6.4
LDH (20%<) 13 0.765 1.1 0.5- 2.5
Tumour size (0%<) 5 0.001 20.6 5.3- 79.9 0.029 5.7 1.2- 27.1
CA19-9 = carbohydrate antigen 19-9, sADC = selected area apparent diffusion coefficient, wADC = whole tumour apparent diffusion coefficient, Pts =
patients, HR = hazard ratio, CI = confidence interval, CEA = carcinoembryonic antigen, LDH = lactate dehydrogenase, CRP = C-reactive protein
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group (n=28) and the negative sADC change group (n=15).
Median PFS was 9.8 months (95 % CI, 0.4–19.2) in the pos-
itive sADC change group, compared to 2.8 months (95 % CI,
1.6–4.0) in the negative sADC change group (p=0.001).
Regarding the correlation with OS, multivariate analysis
identified sADC change and CRP as independent predictive
markers, with sADC change as the strongest (HR, 6.7; 95 %
CI, 2.7–16.6; p=0.001) (Table 3). Median OSs in the positive
sADC change and negative sADC change groups were
15.9 months (HR, 5.1; 95 % CI, 5.9–25.8, n=28) and
5.6 months (HR, 0.70; 95 % CI, 4.2–7.0, n=15; p=0.001),
respectively (Fig. 2b).
Discussion
The current results revealed that sADC change was signifi-
cantly associated with PFS. This means that sADC change can
predict the therapeutic efficacy of chemotherapy for
unresectable pancreatic cancer at 4 weeks after the initiation
of treatment. Our results also demonstrated sADC change as a
strong predictive marker of OS. This was because the survival
period after the failure of first-line chemotherapy was ex-
tremely short. Only 65 % of patients received second-line
chemotherapy and, in addition, the mean treatment duration
with second-line chemotherapy was only 2.8 months (Fig. 3).
In this study, we evaluated minimum ADC values using
two techniques, sADC and wADC. The change in sADC
was a significantly predictive factor for survival, whereas the
change in wADC was not. These results could indicate the
importance of excluding cystic and necrotic areas and vessels
from the measurement areas of ADC. The wADC values
might be also influenced by susceptibility artefacts due to
gastrointestinal air.
RECIST criteria are generally used for the evaluation of
chemotherapy for pancreatic cancer. However, the timing of
assessment is often delayed because performance status has
already become poor by the time the judgement of disease
progression is delivered. The patient could thus lose the op-
portunity to receive effective second-line treatment.
Histological changes in tumour tissues occur prior to changes
in tumour size. DWI can provide information on tissue cellu-
larity and the integrity of cellular membranes [26]. Several
studies have reported that the ADC obtained from DWI is
useful to provide an early prediction of tumour response
[8–11, 13–18].
Previously, Niwa et al. [17] and Cuneo et al. [18] reported
that pretreatment ADC values were useful to evaluate the tu-
mour response in pancreatic cancer. In contrast, our study
demonstrated the effectiveness of relative change in ADC val-
ue during treatment to predict OS and PFS. The measurement
techniques were also different: Niwa et al. [17] and Cuneo
et al. [18] used mean ADC value, while we used minimum
ADC value.
This study evaluated minimumADC due to the mechanism
of tumour growth for pancreatic cancer. Pancreatic stellate
cells, which promote tumour growth, increase deposition of
connective tissue in tumour [27].Muraoka et al. [28] clinically
reported that fibrosis of connective tissue in pancreatic tu-
mour, which showed a low ADC value, was a significant
representation of malignancy. We therefore considered that
changes in the minimum ADC during treatment could repre-
sent the tumour response.
Several studies have examined biomarkers for chemother-
apy for pancreatic cancer. Although the serum CA19-9 level is
the most commonly used in clinical practice, a large-scale
prospective trial showed that a decrease in CA19-9 levels at
Fig. 2 (a) Progression-free survival (PFS) per relative change in selected
area apparent diffusion coefficient (sADC). Patients with positive sADC
change (n=28) showed a significantly better median PFS than patients
with a negative sADC change (n=15) (9.8 months, 95%CI, 0.4–19.2, vs.
2.8 months, 95 % CI, 1.6–4.0 months; p=0.001). (b) Overall survival
(OS) per relative change in sADC. Patients with a positive sADC change
(n=28) had a significantly better median survival than patients with a
negative sADC change (n=15) (15.9 mo, 95 % CI, 5.9–25.8, vs. 5.6
mo, 95 % CI, 4.2– 7.0; p=0.001)
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Table 3 Uni- and multivariate analyses of predictive markers for overall survival
Factors Pts Univariate Multivariate
P HR 95%CI P HR 95%CI
sADC (0% =>) 15 0.001 6.8 3.0- 15.2 0.001 6.7 2.7- 16.6
wtADC (0%=>) 16 0.657 0.9 0.4- 1.7
CA19-9 (20%<) 10 0.602 1.2 0.6- 2.7
CEA (20%<) 10 0.396 1.4 0.6- 3.0
CRP (20%<) 12 0.002 3.3 1.6- 7.0 0.016 2.6 1.2- 5.6
LDH (20%<) 13 0.978 1.0 0.5- 2.0
Tumour size (0%<) 5 0.015 3.4 1.3- 9.0 0.545 0.7 0.2- 2.1
CA19-9 = carbohydrate antigen 19-9, sADC = selected area apparent diffusion coefficient, wADC = whole tumour apparent diffusion coefficient, Pts =
patients, HR = hazard ratio, CI = confidence interval, CEA = carcinoembryonic antigen, LDH = lactate dehydrogenase, CRP = C-reactive protein
Fig. 3 A 59-year-old man with pancreatic head cancer. (a) Contrast-
enhanced CT before initiation of treatment shows encasement of the
coeliac, common hepatic and splenic arteries (arrow), and retroperitoneal
invasion (arrow) by a tumour with a diameter of 6.4 cm arising in the
pancreatic head. (b) Apparent diffusion coefficient (ADC) map obtained
by diffusion-weighted imaging (DWI) before initiation of treatment
shows a low selected area apparent diffusion coefficient (sADC) value
(0.95×10-3 mm2/s) (arrow). (c) T1-weighted image on magnetic
resonance imaging after 4 weeks from starting chemotherapy showed
no change in primary tumour size (6.4 cm in diameter) (arrow). (d)
ADC map obtained by DWI after 4 weeks from starting chemotherapy
demonstrated a decrease in sADC value (0.75×10-3 mm2/s) (arrow). (e)
Contrast-enhanced CT after 8 weeks from starting chemotherapy showed
no change in primary tumour size (diameter, 6.4 cm) (arrow). (f) Contrast-
enhanced CT after 3 months from starting chemotherapy demonstrated
the multiple liver metastases (arrowhead) and the increased primary tu-
mour (arrow). This patient survived for only 5.6 months from the initia-
tion of first-line chemotherapy using gemcitabine
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42 days after starting gemcitabine and/or capecitabine was not
significantly associated with OS [29]. Haas et al. [23] reported
that changes in CEA and CRP during chemotherapy were
independently associated with the prognosis of second-line
chemotherapy. Cutsem et al. [30] also identified changes in
serum CRP and LDH during first-line chemotherapy as prog-
nostic factors [30]. Our results demonstrated a change in min-
imum ADC to be the strongest predictive marker when com-
pared with CA19-9, CEA, LDH, CRP and tumour size.
Gemcitabine and oral fluoropyrimidine are currently
in common use for pancreatic cancer [1, 2, 4–6]. In
cases where gemcitabine is applied as the first-line che-
motherapy and fails, oral fluoropyrimidine is used.
Likewise, in cases where oral fluoropyrimidine is ap-
plied first and fails, gemcitabine is used. To prolong
survival, the regimen to which the tumour is more sen-
sitive should be used first because, as mentioned above,
the opportunities for second-line chemotherapy appear
limited due to the rapid tumour growth with the wors-
ening of the patient’s performance status. To date, no
useful chemo-sensitivity tests have been reported for
pancreatic cancer. According to our results, DWI could
predict chemo-sensitivity in the early period after
starting chemotherapy.
Several limitations must be considered when interpreting
the results of the present study. First, the patient population
was relatively small. Second, the measurement reproducibility
of sADC was not assessed in this study. However, we instead
measured at least five ROIs in each tumour. Third, we per-
formed evaluations only at 4 weeks after the start of chemo-
therapy for ethical reasons. Namely, additional MRI examina-
tions could not be approved by our IRB, since results of this
study did not contribute to decisions on therapeutic strategy.
Because we obtained positive data after 4 weeks, further study
is warranted to elucidate whether it is also possible to detect
the response by performing DWI after 1 or 2 weeks.
In conclusion, the relative change in sADC at 4 weeks from
the initiation of treatment could serve as a sensitive imaging
biomarker for the therapeutic effect and prognosis of
unresectable pancreatic cancer. Further study is needed to clar-
ify the role of ADC in determining treatment strategies for
unresectable pancreatic cancer.
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